Works matching DE "ANTINEOPLASTIC combined chemotherapy protocols"

Results: 382
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

    Published in:
    JNCI Cancer Spectrum, 2024, v. 8, n. 4, p. 1, doi. 10.1093/jncics/pkae054
    By:
    • Ramaswamy, Anant;
    • Bhargava, Prabhat;
    • Dubashi, Biswajit;
    • Gupta, Anuj;
    • Kapoor, Akhil;
    • Srinivas, Sujay;
    • Shetty, Omshree;
    • Jadhav, Poonam;
    • Desai, Veena;
    • Noronha, Vanita;
    • Joshi, Amit;
    • Menon, Nandini;
    • Patil, Vijay M;
    • Mishra, Bal Krishna;
    • Sansar, Bipinesh;
    • Singh, Arpita;
    • Patel, Swapnil;
    • Singh, Satyendra Narayan;
    • Dhal, Ipsita;
    • Vinayak, Kunal Ranjan
    Publication type:
    Article
    10
    11

    Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy.

    Published in:
    Clinical & Translational Immunology, 2021, v. 10, n. 11, p. 1, doi. 10.1002/cti2.1351
    By:
    • Shanavas, Mohamed;
    • Law, Soi‐Cheng;
    • Hertzberg, Mark;
    • Hicks, Rodney J;
    • Seymour, John F;
    • Li, Zhixiu;
    • Merida de Long, Lilia;
    • Nath, Karthik;
    • Sabdia, Muhammed B;
    • Gunawardana, Jay;
    • Gandhi, Maher K;
    • Keane, Colm
    Publication type:
    Article
    12
    13
    14
    15

    Protective effects of ascorbic acid against anticancer drug-induced oxidative stress and genotoxic damage in Saccharomyces cerevisiae.

    Published in:
    3 Biotech, 2025, v. 15, n. 5, p. 1, doi. 10.1007/s13205-025-04280-y
    By:
    • da Mata, Ana Maria Oliveira Ferreira;
    • Silva, Reyca Rodrigues e;
    • Braga, Antônio Lima;
    • de Carvalho, Ricardo Melo;
    • de Oliveira Santos, José Victor;
    • de Alencar, Marcus Vinícius Oliveira Barros;
    • Paz, Márcia Correia Fernanda Jardim;
    • Ansari, Siddique Akber;
    • Ansari, Irfan Aamer;
    • Islam, Muhammad Torequl;
    • de Castro e Sousa, João Marcelo;
    • da Silva, Felipe Cavalcanti Carneiro;
    • de Carvalho Melo Cavalcante, Ana Amélia;
    • da Silva, Benedito Borges
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23

    Assessing the Therapeutic Impacts of HAMLET and FOLFOX on BRAF-Mutated Colorectal Cancer: A Study of Cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo.

    Published in:
    Medicina (1010660X), 2024, v. 60, n. 1, p. 142, doi. 10.3390/medicina60010142
    By:
    • Žilinskas, Justas;
    • Stukas, Darius;
    • Jasukaitienė, Aldona;
    • Žievytė, Inga;
    • Balion, Zbigniev;
    • Šapauskienė, Jurgita;
    • Banienė, Rasa;
    • Paužas, Henrikas;
    • Lizdenis, Paulius;
    • Čėsna, Vaidotas;
    • Dambrauskas, Žilvinas;
    • Gulbinas, Antanas;
    • Tamelis, Algimantas
    Publication type:
    Article
    24
    25
    26

    Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

    Published in:
    PLoS Medicine, 2024, v. 21, n. 5, p. 1, doi. 10.1371/journal.pmed.1004389
    By:
    • Wang, De-Shen;
    • Ren, Chao;
    • Li, Shan-Shan;
    • Fong, William Pat;
    • Wu, Xiao-Jun;
    • Xiao, Jian;
    • Li, Bin-Kui;
    • Zheng, Yun;
    • Ding, Pei-Rong;
    • Chen, Gong;
    • Qiu, Miao-Zhen;
    • Wang, Zhi-Qiang;
    • Wang, Feng-Hua;
    • Luo, Hui-Yan;
    • Wang, Feng;
    • Wang, Xiao-Zhong;
    • Wang, Ling-Yun;
    • Xie, De-Jin;
    • Chen, Tao;
    • Li, Li-Ren
    Publication type:
    Article
    27

    Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.

    Published in:
    Hematological Oncology, 2023, v. 41, n. 4, p. 655, doi. 10.1002/hon.3184
    By:
    • Nizzoli, Maria E.;
    • Manni, Martina;
    • Ghiggi, Chiara;
    • Pulsoni, Alessandro;
    • Musuraca, Gerardo;
    • Merli, Michele;
    • Califano, Catello;
    • Bari, Alessia;
    • Massaia, Massimo;
    • Conconi, Annarita;
    • Musto, Pellegrino;
    • Mannina, Donato;
    • Perrone, Tommasina;
    • Re, Francesca;
    • Galimberti, Sara;
    • Gini, Guido;
    • Capponi, Monia;
    • Vitolo, Umberto;
    • Usai, Sara V.;
    • Stefani, Piero M.
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 421, doi. 10.1002/hon.3164_309
    By:
    • Minson, A.;
    • Verner, E.;
    • Giri, P.;
    • Wong, S. M.;
    • Ratnasingam, S.;
    • Butler, J.;
    • Janowski, W.;
    • Ku, M.;
    • Cheah, C. Y.;
    • Hertzberg, M.;
    • Herbert, K.;
    • Hamad, N.;
    • Yannakou, C. K.;
    • Neeson, P.;
    • Saghebi, J.;
    • Blombery, P.;
    • Robertson, M.;
    • Lau, L. S.;
    • Xie, J.;
    • Seymour, J. F.
    Publication type:
    Article
    39
    40
    41
    42

    FIVE‐YEAR RESULTS OF A PHASE 2 STUDY OF CNS‐ORIENTED THERAPY WITH R‐CHOP FOR UNTREATED INTRAVASCULAR LARGE B‐CELL LYMPHOMA: FINAL ANALYSIS OF THE PRIMEUR‐IVL STUDY.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 46, doi. 10.1002/hon.3163_18
    By:
    • Shimada, K.;
    • Yamaguchi, M.;
    • Kuwatsuka, Y.;
    • Matsue, K.;
    • Sato, K.;
    • Kusumoto, S.;
    • Nagai, H.;
    • Takizawa, J.;
    • Fukuhara, N.;
    • Nagafuji, K.;
    • Miyazaki, K.;
    • Ohtsuka, E.;
    • Okamoto, A.;
    • Uchida, T.;
    • Kayukawa, S.;
    • Wake, A.;
    • Sugita, Y.;
    • Ennishi, D.;
    • Kondo, Y.;
    • Meguro, A.
    Publication type:
    Article
    43
    44

    IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 188, doi. 10.1002/hon.3163_118
    By:
    • Arribas, A.;
    • Napoli, S.;
    • Cascione, L.;
    • Sartori, G.;
    • Cannas, E.;
    • Tarantelli, C.;
    • Spriano, F.;
    • Gaudio, E.;
    • Zucchetto, A.;
    • Rossi, F. M.;
    • Rinaldi, A.;
    • Castro de Moura, M.;
    • Jovic, S.;
    • Pittau, R. Bordone;
    • Stathis, A.;
    • Stussi, G.;
    • Gattei, V.;
    • Brown, J. R.;
    • Esteller, M.;
    • Zucca, E.
    Publication type:
    Article
    45

    Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup>) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 930, doi. 10.1002/hon.3054
    By:
    • Shi, Yuankai;
    • Zhang, Qingyuan;
    • Hong, Xiaonan;
    • Wang, Zhen;
    • Gao, Yuhuan;
    • Zou, Liqun;
    • Cen, Hong;
    • Gui, Lin;
    • Li, Yufu;
    • Feng, Jifeng;
    • Wang, Zhao;
    • Zhang, Mingzhi;
    • Jin, Chuan;
    • Zhang, Weihua;
    • Hu, Jianda;
    • Zheng, Chengyun;
    • Zheng, Zhendong;
    • Zhang, Liling;
    • Chen, Shaoshui;
    • Huang, Yunhong
    Publication type:
    Article
    46
    47

    Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 658, doi. 10.1002/hon.2919
    By:
    • Kraft, Robert M.;
    • Ansell, Stephen M.;
    • Villasboas, Jose C.;
    • Bennani, N. Nora;
    • Wang, Yucai;
    • Habermann, Thomas M.;
    • Thanarajasingam, Gita;
    • Lester, Scott C.;
    • Macon, William;
    • Inwards, David J.;
    • Porrata, Luis F.;
    • Micallef, Ivana N.;
    • Witzig, Thomas E.;
    • Thompson, Carrie A.;
    • Johnston, Patrick B.;
    • Nowakowski, Grzegorz S.;
    • Lin, Yi;
    • Paludo, Jonas
    Publication type:
    Article
    48

    Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 473, doi. 10.1002/hon.2902
    By:
    • D'Angelo, Christopher R.;
    • Hanel, Walter;
    • Chen, Yi;
    • Yu, Menggang;
    • Yang, David;
    • Guo, Ling;
    • Karmali, Reem;
    • Burkart, Madelyn;
    • Ciccosanti, Colleen;
    • David, Kevin;
    • Risch, Zachary;
    • Murga‐Zamalloa, Carlos;
    • Devata, Sumana;
    • Wilcox, Ryan;
    • Savani, Malvi;
    • Courville, Elizabeth L.;
    • Bachanova, Veronika;
    • Rabinovich, Emma;
    • Peace, David;
    • Osman, Fauzia
    Publication type:
    Article
    49
    50

    EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3<sup>RD</sup> PARTY EBV‐SPECIFIC CTL AND IBRUTINIB THERAPY.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 130, doi. 10.1002/hon.91_2629
    By:
    • Gandhi, M.K.;
    • Hoang, T.;
    • Tobin, J.W.;
    • Law, S.C.;
    • Talaulikar, D.;
    • Jain, S.;
    • Vari, F.;
    • Murigneux, V.;
    • Fink, L.;
    • Gunawardana, J.;
    • Gould, C.;
    • Oey, H.;
    • Delecluse, S.;
    • Trappe, R.U.;
    • Merida de Long, L.;
    • Sabdia, M.B.;
    • Bhagat, G.;
    • Hapgood, G.;
    • Blyth, E.;
    • Clancy, L.
    Publication type:
    Article